Susan Finston’s recent post on redefining protein products has raised some debate on the regulatory status of short peptides. What is your opinion? Should short peptides be regulated as small molecules or as biologics? Sound off in the comments on Susan’s post.
The back-issues of the Journal of Commercial Biotechnology more than five years old are now free. For complete access, see the archives at http://commercialbiotechnology.com/issue/archive. The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their […]
Get new actionable insights and updates from BiotechBlog
